Welcome to our dedicated page for Esperion Therape news (Ticker: ESPR), a resource for investors and traders seeking the latest updates and insights on Esperion Therape stock.
Esperion Therapeutics, Inc. (NASDAQ: ESPR) is a commercial-stage biopharmaceutical company focused on cardiometabolic and rare/orphan disease therapies, with an emphasis on oral, once-daily, non-statin treatments for patients with elevated LDL-C who are at risk for cardiovascular disease. This news page aggregates company announcements, clinical updates, partnership developments, and financial disclosures related to Esperion and its products.
Investors and healthcare-focused readers can use this feed to follow Esperion’s progress with NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe), including regulatory milestones, commercialization updates, and guideline-related developments. Recent company communications highlight inclusion of bempedoic acid in major cardiovascular guidelines, presentations of new analyses from the CLEAR Outcomes trial, and expansion of access through partners in Europe, Japan, Canada and other regions.
News items also cover Esperion’s pipeline activities, such as the nomination of ESP-2001, a highly specific allosteric ATP-citrate lyase inhibitor for primary sclerosing cholangitis, and broader ACLY-focused research efforts. Financial and corporate updates, including quarterly results, capital raises via public offerings, and executive appointments, are reported through press releases and Form 8-K filings and are reflected in this news stream.
By reviewing the ESPR news feed, readers can see how Esperion describes its Vision 2040 strategy, commercial execution in the U.S. statin-intolerant market, international launches with partners, and ongoing safety and indication communications for NEXLETOL and NEXLIZET. This page offers a centralized view of the company’s publicly released information over time.
Esperion (NASDAQ: ESPR) provided preliminary full‑year 2025 results and a business update on Jan 11, 2026, and outlined its long‑term Vision 2040 growth strategy. Key preliminary figures: U.S. net product sales $156–$160M (+35%–38% vs 2024), total revenue $400–$408M (+20%–23% vs 2024; ~55%–59% excl. one‑time milestones), and cash & cash equivalents ≈ $168M at year‑end 2025. Q4 retail prescription equivalents rose 34% Y/Y and 11.3% Q/Q. Company expects 2026 operating expenses $210–$245M and announced R&D and global commercial expansion, including IND‑enabling work for ESP‑2001 (PSC) and plans for oral triple combination lipid therapies targeted for commercialization in 2027.
Esperion (NASDAQ: ESPR) will present at J.P. Morgan’s 44th Annual Healthcare Conference on Wednesday, January 14, 2025 with a presentation and fireside chat starting at 2:15 p.m. PT / 5:15 p.m. ET. The event will be available via a live webcast on the company investor website.
A replay will be posted approximately two hours after the call and archived on the company website for about 90 days. Esperion is a commercial-stage biopharmaceutical company marketing two oral, once-daily non-statin LDL-C therapies, with global approvals in >40 countries and a pipeline focused on ACLY biology and treatments for primary sclerosing cholangitis and renal diseases.
Esperion (NASDAQ: ESPR) said bempedoic acid was recommended by the 2025 ACC Scientific Statement for LDL-C lowering in adults with peripheral artery disease (PAD) and diabetes on maximally tolerated statins.
The statement endorses LDL-C reduction >50% and goal <55 mg/dL using therapies with proven cardiovascular benefit, listing bempedoic acid alongside high-intensity statins, ezetimibe, and PCSK9 inhibitors. Analysis cited from CLEAR Outcomes reported a 36% reduction in major adverse limb events (MALE) versus placebo. Product indications and safety risks for NEXLIZET and NEXLETOL are reiterated, including hyperuricemia and tendon rupture warnings.
Esperion (NASDAQ: ESPR) announced inducement equity grants dated December 4, 2025 under its 2017 Inducement Equity Incentive Plan. The company granted an aggregate of 380,000 non‑qualified stock options and 435,536 restricted stock units (RSUs), with John Harlow, the new Chief Commercial Officer, receiving 380,000 options and 424,536 RSUs. The option exercise price is $3.79, equal to the December 4, 2025 closing share price.
Vesting: 25% at the one‑year anniversary of each recipient’s vesting commencement date, then the remaining 75% in twelve equal quarterly installments, subject to continued employment and plan terms.
Esperion (NASDAQ: ESPR) announced that partner Otsuka received National Health Insurance price listing and launched NEXLETOL (bempedoic acid) in Japan on Nov 21, 2025 for treatment of hypercholesterolemia and familial hypercholesterolemia.
Under the collaboration, Esperion will receive a $90 million near-term payment tied to product and pricing approvals, is eligible for additional sales milestone payments, and will earn tiered royalties of 15%–30% on net sales in Japan. The company noted Japan is the third largest global market for cardiovascular prevention, making the launch a significant commercial milestone.
Esperion (NASDAQ: ESPR) will present at the Piper Sandler 37th Annual Healthcare Conference in New York on December 3, 2025 at 3:30 p.m. ET.
Investors can access a live webcast on Esperion's investor website; a replay will be available approximately two hours after the call and archived for about 90 days. Esperion is a commercial-stage biopharmaceutical company developing oral, once-daily, non-statin medicines for patients with elevated LDL-C, supported by the nearly 14,000-patient CLEAR Cardiovascular Outcomes Trial. The company is advancing next-generation ATP citrate lyase inhibitors (ACLYi) and pursuing commercial execution and international partnerships.
Esperion (NASDAQ: ESPR) said partner HLS Therapeutics received Health Canada approval to market NILEMDO (bempedoic acid) for the reduction of LDL-cholesterol in Canadians at risk of cardiovascular disease.
Commercial launch in Canada is expected in Q2 2026. The announcement is positioned as part of Esperion's global strategy to expand access to bempedoic acid products.
The release cites Government of Canada figures that about 2.6 million adults (one in 12 aged 20+) live with diagnosed heart disease and that heart disease is the second leading cause of death in Canada, with roughly 14 adults aged 20+ dying every hour from diagnosed heart disease.
Esperion (NASDAQ: ESPR) presented two post hoc analyses from CLEAR Outcomes at AHA Scientific Sessions 2025 (Nov 7-10). In ~8,200 patients receiving no background lipid‑lowering therapy, bempedoic acid monotherapy lowered LDL‑C by 20.6% at 6 months and reduced MACE‑4 by 14% versus placebo. A separate exploratory analysis reported a 42% lower risk of venous thromboembolism (VTE) with bempedoic acid (106 VTE events over 40.6 months); DVT risk -44% and PE risk -39% versus placebo. Safety profiles were reported as similar for total and serious adverse events; labeling warns about hyperuricemia and tendon rupture.
Esperion (NASDAQ: ESPR) announced that on November 4, 2025 it granted 77,650 restricted stock units (RSUs) to 23 new employees under its 2017 Inducement Equity Incentive Plan pursuant to NASDAQ Rule 5635(c)(4).
The RSUs vest 25% on the one-year anniversary of each recipient’s vesting commencement date and the remaining 75% in twelve equal quarterly installments thereafter, subject to continued employment. The awards are governed by the 2017 Inducement Equity Incentive Plan and individual RSU agreements.
Esperion is a commercial-stage biopharmaceutical company commercializing FDA-approved oral, once-daily non-statin medicines for patients with elevated LDL-C and references the nearly 14,000-patient CLEAR Cardiovascular Outcomes Trial.
Esperion (NASDAQ: ESPR) reported Q3 2025 total revenue of $87.3M, up 69% year‑over‑year, driven by U.S. prescription volume and expanded payer coverage. U.S. net product revenue was $40.7M, up 31% Y/Y. The company announced a settlement with ANDA filer Dr. Reddy’s and three other filers preventing generic marketing of NEXLETOL and NEXLIZET prior to April 2040. Bempedoic acid received a Class I, Level A recommendation in the 2025 ESC/EAS guidelines. Partner Otsuka received Japanese approval and favorable preliminary pricing for NEXLETOL, which will trigger material milestone payments upon final pricing.
Esperion ended Q3 with $92.4M cash, reported a Q3 net loss of $31.3M, reiterated 2025 operating expense guidance of $215M–$235M, and expects sustainable profitability beginning Q1 2026.
FAQ
What is the current stock price of Esperion Therape (ESPR)?
What is the market cap of Esperion Therape (ESPR)?
